Comparison of haemodynamic effects of nifedipine and molsidomine in patients with coronary artery disease. 1989

M Kyriakidis, and G Vyssoulis, and P Sfikakis, and C Kyriakidis, and C Pitsavos, and K Valsamis, and V Nomikos, and P Toutouzas
Hippokration Hospital, University of Athens, Greece.

The haemodynamic effects of oral nifedipine 20 mg and molsidomine 4 mg were compared in 24 patients with coronary artery disease. Molsidomine unlike nifedipine caused a significant fall in mean pulmonary artery pressure and left ventricular end-diastolic pressure. Both drugs caused a significant and comparable reduction in systolic and diastolic blood pressure. Although only nifedipine significantly reduced systemic vascular resistance the difference between the drugs was not significant. The heart rate was significantly increased by nifedipine but not by molsidomine. The ejection phase indices were all increased by molsidomine and the increment in the mean normalized systolic ejection rate was significantly greater than that due to nifedipine. The left ventricular end-systolic volume index decreased significantly after molsidomine but not nifedipine. Neither drug significantly affected left ventricular end diastolic volume index, stroke volume index, maximal rate of rise of left ventricular pressure or left ventricular stroke work index.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008981 Molsidomine A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS. Morsydomine,Corpea,Corvaton,Duracoron,Fali-Cor,Korvatone,MTW-Molsidomin,Molsi 1A Pharma,Molsi-AZU,Molsi-Puren,Molsibeta,Molsicor,Molsidain,Molsidomin,Molsidomin Heumann,Molsidomin Stada,Molsidomin Von Ct,Molsidomin-Ratiopharm,Molsihexal,Molsiket,SIN-10,Sydnopharm,Fali Cor,Heumann, Molsidomin,MTW Molsidomin,Molsi AZU,Molsi Puren,Molsidomin Ratiopharm,SIN 10,SIN10,Von Ct, Molsidomin
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M Kyriakidis, and G Vyssoulis, and P Sfikakis, and C Kyriakidis, and C Pitsavos, and K Valsamis, and V Nomikos, and P Toutouzas
December 1985, European heart journal,
M Kyriakidis, and G Vyssoulis, and P Sfikakis, and C Kyriakidis, and C Pitsavos, and K Valsamis, and V Nomikos, and P Toutouzas
July 1986, Drugs,
M Kyriakidis, and G Vyssoulis, and P Sfikakis, and C Kyriakidis, and C Pitsavos, and K Valsamis, and V Nomikos, and P Toutouzas
November 1986, Acta anaesthesiologica Scandinavica,
M Kyriakidis, and G Vyssoulis, and P Sfikakis, and C Kyriakidis, and C Pitsavos, and K Valsamis, and V Nomikos, and P Toutouzas
October 1993, British journal of clinical pharmacology,
M Kyriakidis, and G Vyssoulis, and P Sfikakis, and C Kyriakidis, and C Pitsavos, and K Valsamis, and V Nomikos, and P Toutouzas
May 1983, British heart journal,
M Kyriakidis, and G Vyssoulis, and P Sfikakis, and C Kyriakidis, and C Pitsavos, and K Valsamis, and V Nomikos, and P Toutouzas
January 1976, Acta anaesthesiologica Scandinavica,
M Kyriakidis, and G Vyssoulis, and P Sfikakis, and C Kyriakidis, and C Pitsavos, and K Valsamis, and V Nomikos, and P Toutouzas
April 1983, Acta anaesthesiologica Scandinavica,
M Kyriakidis, and G Vyssoulis, and P Sfikakis, and C Kyriakidis, and C Pitsavos, and K Valsamis, and V Nomikos, and P Toutouzas
September 1980, British journal of anaesthesia,
M Kyriakidis, and G Vyssoulis, and P Sfikakis, and C Kyriakidis, and C Pitsavos, and K Valsamis, and V Nomikos, and P Toutouzas
January 1977, The Journal of international medical research,
M Kyriakidis, and G Vyssoulis, and P Sfikakis, and C Kyriakidis, and C Pitsavos, and K Valsamis, and V Nomikos, and P Toutouzas
January 1978, British heart journal,
Copied contents to your clipboard!